APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Santiago Clocchiatti‐Tuozzo, Cyprien A. Rivier, Daniela B. Renedo, Shufan Huo, Adam de Havenon, Maximiliano A. Hawkes, Emily J. Gilmore, Lee H. Schwamm et al.. JAMA Neurology, 2025-06-23
Topic: Brain proteins, microglia and lab models
Plain-language summary
Of 413 477 All of Us participants, 2038 were eligible. Their mean (SD) age was 71 (9) years; 918 (45%) were female, 1120 (55%) were male, and 1710 (83%) had European ancestry. Among these participants, 483 (23.7%) were carriers of at least 1 APOE ε4 allele. After a median follow-up of 2.9 years, 26 participants sustained an ICH (cumulative incidence, 1.5%; 95% CI, 1.0%-2.2%), of whom 12 (cumulative incidence, 3.1%; 95% CI, 1.7%-5.3%) were carriers and 14 (cumulative incidence, 1%; 95% CI, 0.6%-1.7%) were noncarriers (P = .007). Multivariable Cox proportional hazard models confirmed this association: compared with noncarriership, APOE ε4 carriership was associated with a 3-fold increase in the risk of ICH (hazard ratio, 3.07; 95% CI, 1.42-6.65). APOE information improved the discrimination of risk prediction scores (C statistic of 0.74 and 0.68 for models with and without APOE, respectively; P = .03). Conclusions and Relevance: Further research is needed to evaluate whether cerebral amyloid angiopathy mediates the observed association and whether APOE e4 information improves clinical decision-making about anticoagulation therapy in patients with atrial fibrillation. The latter is important now that APOE information is used in clinical settings to guide antiamyloid treatment for Alzheimer disease and has been returned to millions of persons by direct-to-consumer genotyping companies.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 26 participants. In people with atrial fibrillation taking apixaban, carrying APOE ε4 was linked to about a threefold higher risk of intracranial hemorrhage. Reported effect size: 23.7%; 1.5%; 1.0%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Clocchiatti‐Tuozzo, S., Rivier, C. A., Renedo, D. B., Huo, S., de Havenon, A., Hawkes, M. A., et al. (2025). APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2025.0182
Vancouver
Clocchiatti‐Tuozzo S, Rivier CA, Renedo DB, Huo S, de Havenon A, Hawkes MA, et al. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology. 2025. doi:10.1001/jamaneurol.2025.0182. PMID: 40549373.
BibTeX
@article{clocchiattituozzo2025-40549373,
author = {Clocchiatti‐Tuozzo, Santiago and Rivier, Cyprien A. and Renedo, Daniela B. and Huo, Shufan and de Havenon, Adam and Hawkes, Maximiliano A. and Gilmore, Emily J. and Schwamm, Lee H. and others},
title = {{APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban}},
journal = {JAMA Neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.0182},
pmid = {40549373},
url = {https://doi.org/10.1001/jamaneurol.2025.0182}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Of 413 477 All of Us participants, 2038 were eligible.
- Their mean (SD) age was 71 (9) years; 918 (45%) were female, 1120 (55%) were male, and 1710 (83%) had European ancestry.
- Among these participants, 483 (23.7%) were carriers of at least 1 APOE ε4 allele.
- After a median follow-up of 2.9 years, 26 participants sustained an ICH (cumulative incidence, 1.5%; 95% CI, 1.0%-2.2%), of whom 12 (cumulative incidence, 3.1%; 95% CI, 1.7%-5.3%) were carriers and 14 (cumulative incidence, 1%; 95% CI, 0.6%-1.7%) were noncarriers (P = .007).
- Multivariable Cox proportional hazard models confirmed this association: compared with noncarriership, APOE ε4 carriership was associated with a 3-fold increase in the risk of ICH (hazard ratio, 3.07; 95% CI, 1.42-6.65).
Why it matters
In people with atrial fibrillation taking apixaban, carrying APOE ε4 was linked to about a threefold higher risk of intracranial hemorrhage. The authors say further research is needed to see whether this association is mediated by cerebral amyloid angiopathy and whether APOE ε4 information improves decisions about anticoagulation therapy.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort study
- Participants26
- Effect size23.7%; 1.5%; 1.0%
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 26 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Guido J. Falcone: h-index 55 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Yale University: institution h-index 1,927 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40549373) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.0182
- PubMed: 40549373
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.